Bon Vivant

Verley, formerly known as Bon Vivant, is a Lyon, France-based industrial biotechnology company that produces animal-free dairy proteins through precision fermentation. The organization operates as a business-to-business ingredient supplier, providing functionalized whey proteins to food and beverage manufacturers for use in sports nutrition and sustainable dairy products. To date, the enterprise has secured a $38 million Series A funding round and an earlier €15 million financing round backed by venture capital investors including Sofinnova Partners and Sparkfood. Verley recently became the first precision fermentation company to receive a No Questions Letter from the Food and Drug Administration for its proprietary proteins, which contain 11% more leucine than conventional whey isolates. Currently scaling its manufacturing capacity to 50,000 liters through agreements with two co-manufacturers, the company was founded by Hélène Briand and Stéphane Mac Millan.

Bon Vivant (now operating as Verley in some communications) is a French precision-fermentation food biotechnology company that produces animal‑free milk proteins (whey and casein variants) for use by food manufacturers seeking sustainable, high‑functionality dairy ingredients[4][3]. Founded in December 2020 and headquartered in Lyon, the company positions itself as a B2B ingredient supplier aiming for commercial scale-up and regulatory approvals in major markets[6][4].

High‑Level Overview

• Mission: Bon Vivant’s mission is to "rethink the way milk is produced" by using precision fermentation to create milk proteins that enable dairy products with lower environmental impact while preserving taste, nutrition and functionality[4].
  - Investment philosophy: (Not applicable — Bon Vivant is a portfolio company / startup rather than an investment firm) — instead, the company has raised venture financing to scale, including a €15M round led by Sofinnova Partners and Sparkfood to accelerate R&D and industrialization[6].
  - Key sectors: Foodtech, precision fermentation, alternative proteins and ingredient supply for the dairy industry[4][6].
  - Impact on the startup ecosystem: Bon Vivant is part of the broader precision‑fermentation wave that validates commercial demand for animal‑free dairy proteins, attracts venture capital into sustainable food ingredients, and creates partnerships between biotech startups and legacy food manufacturers[6][7].

For a portfolio company-style summary (product, customers, problem, growth): Bon Vivant builds precision‑fermented milk proteins (functional whey and casein analogues) sold as B2B ingredients to dairy manufacturers and food formulators seeking lactose‑ and cholesterol‑free proteins with improved processing properties[4][3]. The product solves the environmental, animal‑welfare and supply‑resilience problems of conventional dairy while offering enhanced functional properties (heat/acid tolerance, gelling, high leucine content) for demanding applications[3][4]. The company has shown growth momentum via a sizable Series A/late seed financing (~€15M), regulatory steps including self‑affirmed GRAS in the U.S. for some inputs, product launches (FermWhey range / rebrand to Verley) and plans for commercialization and industrial scale-up in 2024–2025[6][3][7].

Origin Story

• Founding year and leadership: Bon Vivant was founded in December 2020 and is led by co‑founders including CEO Stéphane Mac Millan and CTO/co‑founder Hélène Briand[6][3].
  - Founders’ background and idea emergence: The leadership combines food‑science and biotech expertise focused on precision fermentation to produce milk proteins without animals; the company frames its approach as combining French dairy heritage with modern fermentation technology[3][4].
  - Early traction and pivotal moments: Key early milestones include raising €15M to accelerate R&D and scale, achievement of self‑affirmed GRAS status in the U.S. for certain proteins, public launch of a functional dairy protein portfolio (FermWhey), and rebranding activity to Verley to emphasize functionality and heritage[6][3]. Media interviews and industry coverage (e.g., AgFunder, Protein Production Technology) documented ambitions for mid‑2025 commercialization of whey proteins in the U.S.[7][3].

Core Differentiators

• Product differentiators: Focus on *functionalized* dairy proteins (not just cow‑identical copies) optimized for processing — improved heat/acid tolerance, gelling, and amino‑acid profiles that support nutrition and formulation needs[3].
  - B2B, ingredient‑first model: Sells proteins as ingredients to dairy manufacturers rather than consumer finished goods, positioning itself as a supplier to incumbent food industry players[6].
  - Regulatory and market progress: Achieved self‑affirmed GRAS for U.S. use of some proteins and publicly targets commercialization and industrial production, signaling regulatory and scale‑readiness ambitions[3][6].
  - Technology & IP: Uses precision fermentation with engineered microbes/yeasts and claims proprietary functionalization that tailors proteins for industrial processing and sensory performance[3].
  - Strategic funding and partnerships: Backed by investors active in food and climate tech (Sofinnova Partners, Sparkfood), enabling capital for scale and industry connections[6].

Role in the Broader Tech Landscape

• Trend alignment: Bon Vivant sits at the intersection of precision fermentation, alternative proteins, and sustainable ingredient supply, a trend driven by environmental pressures, supply volatility, and demand for high‑protein products[4][7].
  - Why timing matters: Rising market demand for high‑protein dairy formats, tightening sustainability targets across food supply chains, and maturing fermentation scale‑up capabilities create a window for B2B protein suppliers to win mainstream adoption[7][6].
  - Market forces in their favor: Growing consumer and buyer interest in animal‑free ingredients, increasing regulatory pathways for fermentation‑derived proteins, and large incumbent food companies seeking decarbonization and supply‑diversification partners[6][7].
  - Influence on ecosystem: By commercializing functional animal‑free dairy proteins, Bon Vivant helps validate precision fermentation as a practical route for formulators, accelerates investment into fermentation capacity, and raises technical expectations for ingredient functionality (not only mimicry)[3][6].

Quick Take & Future Outlook

• What’s next: Short‑term priorities are industrial scale‑up, regulatory clearances in additional markets, expanding the product suite (caseins in addition to whey), and securing industrial partners or own manufacturing capacity to meet B2B demand[6][7][3].
  - Shaping trends: Adoption will be shaped by price parity vs. conventional dairy proteins, demonstrated functional advantages in finished products, and the speed at which customers accept fermentation‑derived ingredients in their supply chains[7][3].
  - Potential evolution of influence: If Bon Vivant succeeds in delivering cost‑competitive, functionally superior proteins at scale, it could become a strategic supplier for major dairy brands and catalyze broader displacement of animal‑derived protein fractions in processed dairy categories[6][3].
  - Main risk factors: Technical scale‑up challenges, regulatory variability across geographies, customer conservatism in reformulating legacy products, and competitive pressure from other precision‑fermentation players and alternative‑protein approaches[6][7].

Quick take: Bon Vivant (Verley) is a technically focused, B2B precision‑fermentation ingredient company that distinguishes itself by delivering *functional* dairy proteins for industrial use; its near‑term success hinges on scaling, regulatory acceptance, and proving commercial advantages to legacy dairy manufacturers[3][6][4].